000132534 001__ 132534
000132534 005__ 20240229105022.0
000132534 0247_ $$2doi$$a10.1093/neuonc/nox160
000132534 0247_ $$2pmid$$apmid:29016808
000132534 0247_ $$2pmc$$apmc:PMC5817966
000132534 0247_ $$2ISSN$$a1522-8517
000132534 0247_ $$2ISSN$$a1523-5866
000132534 0247_ $$2altmetric$$aaltmetric:24261416
000132534 037__ $$aDKFZ-2018-00218
000132534 041__ $$aeng
000132534 082__ $$a610
000132534 1001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b0$$eFirst author$$udkfz
000132534 245__ $$aMolecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
000132534 260__ $$aOxford$$bOxford Univ. Press$$c2018
000132534 3367_ $$2DRIVER$$aarticle
000132534 3367_ $$2DataCite$$aOutput Types/Journal article
000132534 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659958231_8494
000132534 3367_ $$2BibTeX$$aARTICLE
000132534 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132534 3367_ $$00$$2EndNote$$aJournal Article
000132534 520__ $$aO6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma. We investigated whether this marker furthermore defines a molecularly distinct tumor subtype with clinically different outcome.We analyzed copy number variation (CNV) and methylation profiles of 1095 primary and 92 progressive isocitrate dehydrogenase wildtype glioblastomas, including paired samples from 49 patients. DNA mutation data from 182 glioblastoma samples of The Cancer Genome Atlas (TCGA) and RNA expression from 107 TCGA and 55 Chinese Glioma Genome Atlas samples were analyzed.Among untreated glioblastomas, MGMT promoter methylated (mMGMT) and unmethylated (uMGMT) tumors did not show different CNV or specific gene mutations, but a higher mutation count in mMGMT tumors. We identified 3 methylation clusters. Cluster 1 showed the highest average methylation and was enriched for mMGMT tumors. Seventeen genes including gastrulation brain homeobox 2 (GBX2) were found to be hypermethylated and downregulated on the mRNA level in mMGMT tumors. In progressive glioblastomas, platelet derived growth factor receptor alpha (PDGFRA) and GLI2 amplifications were enriched in mMGMT tumors. Methylated MGMT tumors gain PDGFRA amplification of PDGFRA, whereas uMGMT tumors with amplified PDGFRA frequently lose this amplification upon progression. Glioblastoma patients surviving <6 months and with mMGMT harbored less frequent epidermal growth factor receptor (EGFR) amplifications, more frequent TP53 mutations, and a higher tumor necrosis factor-nuclear factor-kappaB (TNF-NFκB) pathway activation compared with patients surviving >12 months.MGMT promoter methylation status does not define a molecularly distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT glioblastomas and mMGMT tumors of patients with short survival tend to have more unfavorable molecular profiles.
000132534 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132534 588__ $$aDataset connected to CrossRef, PubMed,
000132534 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b1$$udkfz
000132534 7001_ $$0P:(DE-He78)970bd627f415e0a127210d2cecf2311f$$aSadik, Ahmed$$b2$$udkfz
000132534 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b3$$udkfz
000132534 7001_ $$0P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aHertenstein, Anne$$b4$$udkfz
000132534 7001_ $$aReifenberger, Guido$$b5
000132534 7001_ $$aZacher, Angela$$b6
000132534 7001_ $$aSabel, Michael$$b7
000132534 7001_ $$0P:(DE-HGF)0$$aTabatabai, Ghazaleh$$b8
000132534 7001_ $$0P:(DE-HGF)0$$aSteinbach, Joachim$$b9
000132534 7001_ $$0P:(DE-HGF)0$$aSure, Ulrich$$b10
000132534 7001_ $$0P:(DE-HGF)0$$aKrex, Dietmar$$b11
000132534 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-L$$b12
000132534 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b13$$udkfz
000132534 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b14$$udkfz
000132534 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b15$$udkfz
000132534 7001_ $$aWeller, Michael$$b16
000132534 7001_ $$0P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aOpitz, Christiane$$b17$$udkfz
000132534 7001_ $$aBendszus, Martin$$b18
000132534 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b19$$udkfz
000132534 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b20$$udkfz
000132534 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b21$$eLast author$$udkfz
000132534 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox160$$gVol. 20, no. 3, p. 367 - 379$$n3$$p367 - 379$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000132534 909CO $$ooai:inrepo02.dkfz.de:132534$$pVDB
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)970bd627f415e0a127210d2cecf2311f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000132534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000132534 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132534 9141_ $$y2018
000132534 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000132534 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132534 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000132534 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132534 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132534 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132534 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132534 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132534 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132534 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132534 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000132534 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x0
000132534 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000132534 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x2
000132534 9201_ $$0I:(DE-He78)G161-20160331$$kG161$$lBrain Cancer Metabolism$$x3
000132534 9201_ $$0I:(DE-He78)L801-20160331$$kL801$$lDKTK Tübingen$$x4
000132534 9201_ $$0I:(DE-He78)L601-20160331$$kL601$$lDKTK Freiburg$$x5
000132534 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lBewerunge-Hudler$$x6
000132534 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x7
000132534 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x8
000132534 980__ $$ajournal
000132534 980__ $$aVDB
000132534 980__ $$aI:(DE-He78)G370-20160331
000132534 980__ $$aI:(DE-He78)L101-20160331
000132534 980__ $$aI:(DE-He78)G380-20160331
000132534 980__ $$aI:(DE-He78)G161-20160331
000132534 980__ $$aI:(DE-He78)L801-20160331
000132534 980__ $$aI:(DE-He78)L601-20160331
000132534 980__ $$aI:(DE-He78)W110-20160331
000132534 980__ $$aI:(DE-He78)G160-20160331
000132534 980__ $$aI:(DE-He78)B062-20160331
000132534 980__ $$aUNRESTRICTED